IXC
Click for more information
8.33% 6.5¢ invex therapeutics ltd

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-17

  1. farmerb22
    1,039 Posts.
    lightbulb Created with Sketch. 79
    clock Created with Sketch.
    13/07/23
    10:00
    Post #: 68762674
    I guess its just amazing that when the Invex announcement came regarding the "Granted European Orphan Drug Designation for TBI", the share price spiked from 38 cents to 60 cents.

    Now the company is worth less than the cash in the company. Cash burn should also slow down going forward. Maybe no possibility of other opportunities arising for this company.
    IXC Price at posting: 18.0¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

AHK Ark Mines defines significant exploration target at Sandy Mitchell rare earths project
right-arrow Created with Sketch.
NEWS Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25
right-arrow Created with Sketch.
AVA Ava Risk Group expands US presence with A$0.7M Substation Deal
right-arrow Created with Sketch.
BIO Biome posts record sales revenue of $13M in FY24 – up 80% vs pcp and higher than forecast
right-arrow Created with Sketch.
NEWS Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker
right-arrow Created with Sketch.
ITM iTech lifts MRE at Eyre Peninsula Graphite Project by 300%
right-arrow Created with Sketch.
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
(20min delay)
Last
6.5¢ 		Change
0.005(8.33%) 		Mkt cap ! $4.885M
Open High Low Value Volume
6.5¢ 6.5¢ 6.5¢ $1.02K 15.68K

Buyers (Bids)

No. Vol. Price($)
1 31311 6.6¢
 

Sellers (Offers)

Price($) Vol. No.
7.7¢ 7950 1
View Market Depth
Last trade - 10.07am 02/07/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.